Research and Markets (http://www.researchandmarkets.com/research/76a5d2/the_pharmaceutical)
has announced the addition of the "The
Pharmaceutical Market: Portugal" report to their offering.
This in-depth pharmaceutical market report is ideal for executives
wanting to understand the key drivers in pharmaceutical markets and have
access to a wealth of statistical data. Each report opens with an
outlook section that provides analysis of the market, 5-year market
forecasts, national data projections, market outlook and key
developments such as regulation, pricing/reimbursement, intellectual
property, health facilities and government policy. The report also
provides extensive background information, population trends, health
status, health expenditure, organisation & administration, hospital
services, medical personnel, healthcare development, market access
information, trade data for raw materials and finished products and
essential industry contacts. Included with the report are 3 free
quarterly updated outlook reports, enabling you to keep up to date with
market developments for a year.
Executive Summary
In 2009, the Portuguese pharmaceutical market is valued at US$6.6
billion at retail prices. Pharmacy sales represent over 80% of the
market. Pharmaceutical imports increased by 11.8% in 2007, reaching
US$2.4 billion. Although exports rose by 29.0% in 2007, the deficit of
trade increased, and was valued at US$1.9 billion in 2007. Finished
medicaments exports made up 94% of pharmaceuticals exports and increased
by 30% in 2007.
The performance of generics in the market has improved considerably.
From January to November 2008, generics represented 18.8% and 13.6% of
the pharmacy sector by value and volume. This was equal to sales of
US$890.7 million and 229 million units, respectively. There are about
122 authorised generics producers in Portugal, but market concentration
among leading producers is high.
Hospital drug sales amounted to US$1,083.5 million in 2007. In volume
terms, they stood at 200.4 million units. Oncology and infectology were
the leading therapeutic areas by sales value, with a combined 38.0% of
hospital sales. A National Code for Hospital Drugs (CHNM) has been
implemented to better monitor and co-ordinate hospital sales.
Domestic pharmaceutical production is increasing but is still far from
the levels registered by the six leading countries in the EU-15. In
2004, production stood at 1.6 billion euros (US$2.0 billion). Using data
from 15 local producers, production was estimated at 471 million euros
(US$586 million) in 2005, which represented an increase of 12.9% over
2004.
A new pharmacy regulatory environment was established in August 2007.
Since March 2007, a new drug price system has also been in place. In
2006, Portugal transposed its national regulation for human
pharmaceuticals to the relevant European Directives. Other measures in
2006 included new rules to purchase hospital medicines.
Key Topics Covered:
-
EXECUTIVE SUMMARY
-
Market Structure
-
Pharmacy Sector
-
SNS Sales
-
Generics Sector
-
OTC Sector
-
Domestic Production
-
Pharmaceutical Production in 2004
-
Exports
-
Research & Development
-
Pharmaceutical Regulatory Analysis
-
Patent Protection & Intellectual Property Rights
-
Pricing & Reimbursement
-
EU Directive on the Transparency of Pricing & Reimbursement
-
GROQUIFAR
-
New Pharmacy Regulation
-
New Regulation for Human Pharmaceuticals
-
Trade Fairs
-
EXPOFARMA 2008
-
Trade Associations
-
APIFARMA
-
APOGEN
-
Healthcare Analysis
-
Demographics
-
Incidence of Communicable Disease
-
HIV/AIDS
-
Healthcare System
-
DIRECTORY
-
List of Tables
-
List of Figures
Companies Mentioned Include:
-
Bial
-
Bluepharma
-
Hikma Farmacêutica Portugal
-
Hovione
-
Jaba
-
Medinfar
-
Labotorios Vitória
-
Pharmout
-
Apifarma
-
Apogen
For more information visit http://www.researchandmarkets.com/research/76a5d2/the_pharmaceutical
Source: Espicom Business Intelligence Ltd
Subscribe